Proinflammatory cytokine interleukin-2 (IL-2) is of particular interest for cancer immunotherapy as it plays a critical role in the regulation of immune cells such as T cells. Although proinflammatory cytokines have been used to treat various cancers including metastatic melanoma and renal carcinomas, it has a short blood half-life and the high-dose infusion regimens required result in off-target effects and toxicity in patients.
Read this publication review to learn how researchers used a clinically translatable cytokine delivery platform in an ovarian mouse model validated using non-invasive, longitudinal in vivo optical imaging.